The JPEO-CBRND manages the U.S. Department of Defense’s investments in CBRN defense equipment and medical countermeasures, including development, acquisition, and lifecycle support. Humanetics holds an OTA contract with JPEO-CBRND to develop BIO 300.
Humans face ionizing radiation exposure from cancer treatment, radiological events, or nuclear incidents, with effects ranging from mild tissue damage to fatal outcomes in severe cases.
BIO 300 utilizes a patented nanoparticle oral suspension, which significantly enhances bioavailability and creates near linear absorption characteristics.
Radiotherapy is employed in the treatment of over half of all cancer patients in an effort to kill cancer cells. Unfortunately, many patients incur damage to normal (non-cancerous) tissues in the path of the radiation beam or in areas surrounding the tumor. Additionally, tumors recur in approximately half the patients treated with curative intent. Minimizing normal tissue damage, while increasing the killing effect from radiotherapy on the tumor would improve treatment efficacy and patient quali
BIO 300 has a robust multi-species safety and toxicology database, which has enabled Humanetics to open three active Investigational New Drug applications and proceed to human trials.
Serebrenik AA, Verduyn CW, Kaytor MD. Safety, Pharmacokinetics, and Biomarkers of an Amorphous Solid Dispersion of Genistein, a Radioprotectant, in Healthy Volunteers. 2023;12(2):190-201. PubMed PMID: 36301689.
Artur A. Serebrenik, Ph.D., oversees product development for Humanetics. He manages government-funded initiatives, including grants from the National Institutes of Health (NIH) and the Department of Defense (DoD), and holds a doctorate in Pharmacology.
Rear Admiral Colin Chinn, M.D., MHS, FACP, serves as the company’s Chief Medical Officer. He previously led medical affairs as the 14th Joint Staff Surgeon and held roles in clinical, academic, research, and executive medicine in the U.S. Navy.
Michael D. Kaytor, Ph.D., is the Chief Scientific Officer of Humanetics. Previously, he worked as a Principal Scientist at Medtronic, Inc., evaluating therapy opportunities and leading cross-functional teams.
Ronald J. Zenk, MBA, is a founder of the company and has served as its CEO and an internal director since 1988. He oversees strategic direction, funding, legal and accounting functions, resource deployment, operations, and government relations.
Timothy E. Morris is the Chief Operating Officer and an internal director of the company. He manages Aacolade Pharma LLC, a consulting firm for biotech and pharmaceutical companies, and previously held CFO and COO roles at Opthea Limited and Humanigen, Inc.
Humanetics is a privately held, clinical-stage pharmaceutical company developing drugs to protect against and treat harm from radiation, chemical agents, and biological threats.
Humanetics has a robust and expanding estate of issued patents and pending applications that protect the formulation, method of manufacturing, and uses of BIO 300. Patents are pursued internationally, where market opportunity and enforceability dictate.